Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2025-02-26 Director's Dealing
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 276.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the indirect interest, and the value of the transaction. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, earnings, or management discussion, nor is it an announcement of a report publication. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3329 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement.
2025-02-26 English
Application for quotation of securities - PYC 5 pages 16.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, references previous announcements (Appendix 3B), and provides information about issued capital following the quotation. This type of document is a formal announcement related to capital changes, specifically the listing or quotation of new shares on the exchange. It is not a financial report, earnings release, or management discussion. The document fits the category of Share Issue/Capital Change announcements, as it concerns the issuance and quotation of new securities.
2025-02-25 English
Retail Entitlement Offer Booklet 82 pages 2.2MB
Capital/Financing Update Classification · 95% confidence The document is titled 'Retail Offer Booklet' and describes a pro-rata accelerated non-renounceable entitlement offer of new shares by PYC Therapeutics Limited. It includes detailed information about the offer price, use of proceeds, underwriting, and eligibility for retail shareholders. The document is clearly related to a capital raising event and provides instructions and terms for shareholders to participate in the offer. There is no indication that this is a full financial report, earnings release, or regulatory filing unrelated to capital raising. The content matches the definition of a Capital/Financing Update, which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual offer booklet itself.
2025-02-23 English
Despatch of Retail Offer Document 2 pages 209.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the despatch of a Retail Offer Booklet related to an accelerated non-renounceable entitlement offer. It includes details about the offer period, issue price, and instructions for shareholders to participate. The document does not contain financial statements or detailed financial analysis but rather informs shareholders about the commencement and details of a capital raising event. The document length is 2714 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Capital/Financing Update (CAP).
2025-02-23 English
Despatch of Notice to Ineligible Retail Shareholders 5 pages 479.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from PYC Therapeutics Limited regarding an accelerated non-renounceable entitlement offer. It informs certain shareholders (ineligible retail shareholders) that they are not eligible to participate in the entitlement offer and explains the reasons for this ineligibility. The document includes details about the offer, eligibility criteria, and the appointment of a nominee to sell shares on behalf of ineligible shareholders. It is a regulatory announcement related to capital raising but does not contain financial statements or detailed financial analysis. It is not a full financial report, earnings release, or management discussion. The document is a formal notification about a capital raising event and shareholder eligibility, fitting the category of Capital/Financing Update (CAP). The document length is 9842 characters, which is substantive and not a mere brief announcement or report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP) with high confidence.
2025-02-23 English
Completion of Institutional Entitlement Offer 3 pages 270.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement dated 19 February 2025 regarding the completion of the institutional component of an entitlement offer by PYC Therapeutics Limited. It details the amount raised (~$91 million), the total expected raise (~$146 million), and the terms of the retail entitlement offer. The text includes forward-looking statements and references to previous ASX announcements and investor presentations. There are no financial statements or detailed financial analysis included, only a summary of the capital raising event. The document is not a full financial report, earnings release, or management discussion. It is clearly an update on the company's fundraising activity and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6331 characters) and content confirm it is not merely a brief announcement of a report but a substantive update on financing.
2025-02-18 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.